EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.

Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability ...

Today, the European Medicines Agency’s Committee for Medicinal Products for Human Use, CHMP, issued a positive opinion for a ...

Novo Nordisk's Wegovy consumption jumped 70% after price cuts, lifting share in November. Eli Lilly's Mounjaro still led anti ...

Novo Nordisk ( NVO 2.28%) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...

Novo Nordisk A/S said its high-dose version of blockbuster Wegovy has been cleared by the European Union’s drug advisory board, opening the way for use of a shot that delivers more weight loss than ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended granting approval to Novo Nordisk India for its proposed update to ...

How much Novo Nordisk’s weight-loss drug Wegovy costs can depend on a lot of things, which makes it very hard for the average ...

Dec 2 () - Wegovy maker Novo Nordisk is planning ​to test its experimental obesity drug, ‌CagriSema, in overweight children ...